

HENRY SCHEIN INC  
Form 10-Q  
November 08, 2006

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 10-Q**

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2006**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number: 0-27078**

**HENRY SCHEIN, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware  
(State or other jurisdiction of  
incorporation or organization)**

**11-3136595  
(I.R.S. Employer Identification No.)**

**135 Duryea Road  
Melville, New York  
(Address of principal executive offices)  
11747  
(Zip Code)**

**Registrant's telephone number, including area code: (631) 843-5500**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer" and "large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

As of November 1, 2006, there were 88,573,415 shares of the registrant's common stock outstanding.

**HENRY SCHEIN, INC.**  
**INDEX**

	<b>Page</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
<b><u>ITEM 1. Consolidated Financial Statements:</u></b>	
<u>Balance Sheets as of September 30, 2006 and December 31, 2005</u>	3
<u>Statements of Income for the three and nine months ended September 30, 2006 and September 24, 2005</u>	4
<u>Statements of Cash Flows for the nine months ended September 30, 2006 and September 24, 2005</u>	5
<u>Notes to Consolidated Financial Statements</u>	6
<b><u>ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>	16
<b><u>ITEM 3. Quantitative and Qualitative Disclosures About Market Risk</u></b>	28
<b><u>ITEM 4. Controls and Procedures</u></b>	29
<b><u>PART II. OTHER INFORMATION</u></b>	
<b><u>ITEM 1. Legal Proceedings</u></b>	30
<b><u>ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds</u></b>	31
<b><u>ITEM 6. Exhibits</u></b>	32
<b><u>Signature</u></b>	32
<u>EX-31.1: CERTIFICATION</u>	
<u>EX-31.2: CERTIFICATION</u>	
<u>EX-32.1: CERTIFICATION</u>	

**Table of Contents**

**PART I. FINANCIAL INFORMATION**  
**ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS**  
**HENRY SCHEIN, INC.**  
**CONSOLIDATED BALANCE SHEETS**  
**(in thousands, except share and per share data)**

	<b>September 30, 2006  (unaudited)</b>	<b>December 31, 2005 (Adjusted - Notes 3 &amp; 7)</b>
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 176,070	\$ 210,683
Available-for-sale securities		124,010
Accounts receivable, net of reserves of \$41,893 and \$52,308	605,058	582,617
Inventories, net	572,569	505,542
Deferred income taxes	28,629	35,505
Prepaid expenses and other	134,324	126,052
 Total current assets	 1,516,650	 1,584,409
Property and equipment, net	218,154	190,746
Goodwill	751,664	626,869
Other intangibles, net	161,423	123,204
Investments and other	69,729	57,892
 Total assets	 \$ 2,717,620	 \$ 2,583,120
 <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 365,704	\$ 371,392
Bank credit lines	2,550	2,093
Current maturities of long-term debt	40,617	33,013
Accrued expenses:		
Payroll and related	95,705	96,113
Taxes	54,345	65,070
Other	165,325	156,433
 Total current liabilities	 724,246	 724,114
Long-term debt	456,487	489,520
Deferred income taxes	55,353	54,432
Other liabilities	58,260	53,547
 Minority interest	 16,497	 12,353
Commitments and contingencies		
 Stockholders' equity:		

Edgar Filing: HENRY SCHEIN INC - Form 10-Q

Preferred stock, \$.01 par value, 1,000,000 shares authorized, none outstanding

Common stock, \$.01 par value, 240,000,000 shares authorized, 88,555,830 outstanding on September 30, 2006 and 87,092,238 outstanding on December 31, 2005

	886	871
Additional paid-in capital	610,717	559,266
Retained earnings	754,010	667,958
Accumulated other comprehensive income	41,164	21,059

Total stockholders' equity	1,406,777	1,249,154
----------------------------	-----------	-----------

Total liabilities and stockholders' equity	\$ 2,717,620	\$ 2,583,120
--	--------------	--------------

See accompanying notes.

Table of Contents

**HENRY SCHEIN, INC.**  
**CONSOLIDATED STATEMENTS OF INCOME**  
(in thousands, except per share data)  
(unaudited)

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30, 2006</b>	<b>September 24, 2005 (Adjusted - Note 3)</b>	<b>September 30, 2006</b>	<b>September 24, 2005 (Adjusted - Note 3)</b>
Net sales	\$ 1,272,020	\$ 1,125,363	\$ 3,654,161	\$ 3,292,788
Cost of sales	911,014	808,632	2,596,093	2,353,327
Gross profit	361,006	316,731	1,058,068	939,461
Operating expenses:				
Selling, general and administrative	298,331	258,352	857,727	760,762
Operating income	62,675	58,379	200,341	178,699
Other income (expense):				
Interest income	3,503	1,942	12,028	4,469
Interest expense	(6,541)	(6,976)	(21,237)	(18,286)
Other, net	2,298	1,028	2,180	915
Income from continuing operations before taxes, minority interest and equity in earnings of affiliates	61,935	54,373	193,312	165,797
Income taxes	(21,715)	(19,907)	(69,316)	(60,979)
Minority interest in net income of subsidiaries	(1,181)	(1,241)	(4,447)	(3,755)
Equity in earnings of affiliates	246	79	581	514
Income from continuing operations	39,285	33,304	120,130	101,577
Discontinued operations:				
Loss from operations of discontinued components		(16,951)	(32,279)	(17,399)
Income tax benefit		6,948	12,911	6,953
Loss on discontinued operations		(10,003)	(19,368)	(10,446)
Net income	\$ 39,285	\$ 23,301	\$ 100,762	\$ 91,131
Earnings from continuing operations per share:				
Basic	\$ 0.44	\$ 0.38	\$ 1.37	\$ 1.17
Diluted	\$ 0.44	\$ 0.37	\$ 1.34	\$ 1.15

Loss from discontinued operations per share:

Basic	\$		\$	(0.11)	\$	(0.22)	\$	(0.12)
-------	----	--	----	--------	----	--------	----	--------

Diluted	\$		\$	(0.11)	\$	(0.21)	\$	(0.12)
---------	----	--	----	--------	----	--------	----	--------

Earnings per share:

Basic	\$	0.44	\$	0.27	\$	1.15	\$	1.05
-------	----	------	----	------	----	------	----	------

Diluted	\$	0.44	\$	0.26	\$	1.13	\$	1.03
---------	----	------	----	------	----	------	----	------

Weighted-average common shares outstanding:

Basic	88,291	87,232	87,820	86,975
-------	--------	--------	--------	--------

Diluted	90,015	88,636	89,554	88,423
---------	--------	--------	--------	--------

See accompanying notes.

Table of Contents

**HENRY SCHEIN, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(in thousands)  
(unaudited)

	Nine Months Ended	
	September 30, 2006	September 24, 2005 (Adjusted - Notes 3 & 7)
<b>Cash flows from operating activities:</b>		
Net income	\$ 100,762	\$ 91,131
Adjustments to reconcile net income to net cash provided by operating activities:		
Loss on sale of discontinued operation, net of tax	19,363	
Depreciation and amortization	46,891	42,547
Impairment from write-down of long-lived asset		11,928
Stock-based compensation expense	13,933	13,364
Provision for losses on trade and other accounts receivable	2,343	5,635
Deferred income taxes	(2,662)	(3,663)
Stock issued to 401(k) plan	3,565	3,223
Undistributed earnings of affiliates	(581)	(514)
Minority interest in net income of subsidiaries	4,447	3,755
Other	(2,549)	1,066
Changes in operating assets and liabilities, net of acquisitions:		
Accounts receivable	(9,418)	(41,645)
Inventories	(35,967)	34,125
Other current assets	7,376	34,118
Accounts payable and accrued expenses	(82,877)	(89,022)
Net cash provided by operating activities	64,626	106,048
<b>Cash flows from investing activities:</b>		
Purchases of fixed assets	(49,927)	(36,204)
Payments for business acquisitions, net of cash acquired	(186,132)	(58,548)
Cash received from business divestiture	36,527	
Purchases of available-for-sale securities	(164,037)	(24,745)
Proceeds from sales of available-for-sale securities	286,767	
Proceeds from maturities of available-for-sale securities	1,280	
Proceeds from settlement of note receivable		11,779
Net proceeds from (payments for) foreign exchange forward contract settlements	(16,895)	23,630
Other	(6,604)	573
Net cash used in investing activities	(99,021)	(83,515)

**Cash flows from financing activities:**

Proceeds from (repayments of) bank borrowings	297	(2,888)
Principal payments for long-term debt	(30,677)	(5,478)
Payments for debt issuance costs		(650)
Proceeds from issuance of stock upon exercise of stock options	32,900	25,278
Payments for repurchases of common stock	(25,700)	(27,117)
Proceeds from excess tax benefits related to stock-based compensation	13,150	7,534
Other	1,665	(3,614)
Net cash used in financing activities	(8,365)	(6,935)
Net change in cash and cash equivalents	(42,760)	15,598
Effect of exchange rate changes on cash and cash equivalents	8,147	1,538
Cash and cash equivalents, beginning of period	210,683	186,621
Cash and cash equivalents, end of period	\$ 176,070	\$ 203,757

See accompanying notes.

**Table of Contents**

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in thousands, except share and per share data)**  
**(unaudited)**

**Note 1. Basis of Presentation**

Our consolidated financial statements include our accounts, as well as those of our wholly-owned and majority-owned subsidiaries. Certain prior period amounts have been reclassified to conform to the current period presentation.

Our accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ( U.S. GAAP ) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements.

The consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2005.

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the nine months ended September 30, 2006 are not necessarily indicative of the results to be expected of any other interim period or for the year ending December 30, 2006.

**Note 2. Segment Data**

We conduct our business through two reportable segments: healthcare distribution and technology. These segments offer different products and services to the same customer base. The healthcare distribution reportable segment aggregates our dental, medical (including animal health) and international operating segments. Products distributed include consumable products, small equipment, laboratory products, large equipment, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Our dental group serves office-based dental practitioners, schools and other institutions in the combined United States and Canadian dental market. Our medical group serves office-based medical practitioners, surgical centers, other alternate-care settings, animal health clinics and other institutions throughout the United States. Our international group serves 17 countries outside of North America and is what we believe to be a leading European healthcare supplier serving office-based practitioners.

Our technology group provides software, technology and other value-added services to healthcare practitioners, primarily in the United States and Canada. Our value-added practice solutions include practice-management software systems for dental and medical practitioners and animal health clinics. Our technology group offerings also include financial services and continuing education services for practitioners.

**Table of Contents**

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(in thousands, except share and per share data)  
(unaudited)

**Note 2. Segment Data (Continued)**

The following tables present information about our business segments:

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September</b>	<b>September</b>	<b>September</b>	<b>September</b>
	<b>30,</b>	<b>24,</b>	<b>30,</b>	<b>24,</b>
	<b>2006</b>	<b>2005</b>	<b>2006</b>	<b>2005</b>
<b>Net Sales:</b>				
Healthcare distribution (1):				
Dental (2)	\$ 538,493	\$ 462,514	\$ 1,532,399	\$ 1,361,183
Medical (3)	381,435	350,185	1,064,669	968,633
International (4)	327,499	291,701	986,338	898,479
Total healthcare distribution	1,247,427	1,104,400	3,583,406	3,228,295
Technology (5)	24,593	20,963	70,755	64,493
Total	\$ 1,272,020	\$ 1,125,363	\$ 3,654,161	\$ 3,292,788

- (1) Consists of consumable products, small equipment, laboratory products, large equipment, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
- (2) Consists of products sold in the United States and Canada.
- (3) Consists of products sold in the United States medical and animal health markets.
- (4) Consists of products sold in the dental,

medical and animal health markets, primarily in Europe.

- (5) Consists of practice-management software and other value-added products and services, which are distributed primarily to healthcare providers in the United States and Canada.

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September</b>	<b>September</b>	<b>September</b>	<b>September</b>
	<b>30,</b>	<b>24,</b>	<b>30,</b>	<b>24,</b>
	<b>2006</b>	<b>2005 (1)</b>	<b>2006</b>	<b>2005 (1)</b>
<b>Operating Income:</b>				
Healthcare distribution	\$ 54,245	\$ 50,604	\$ 174,022	\$ 154,149
Technology	8,430	7,775	26,319	24,550
<b>Total</b>	<b>\$ 62,675</b>	<b>\$ 58,379</b>	<b>\$ 200,341</b>	<b>\$ 178,699</b>

- (1) Adjusted to reflect the effect of our adoption of FAS 123(R) using the modified retrospective application as discussed in Note 3.

**Table of Contents**

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**(in thousands, except share and per share data)**  
**(unaudited)**

**Note 3. Stock-Based Compensation**

Effective January 1, 2006, we adopted the provisions of Statement of Financial Accounting Standards (FAS) No. 123(R), Share-Based Payment. We previously applied Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and related Interpretations and provided the required pro forma disclosures of FAS 123, Accounting for Stock-Based Compensation in our consolidated financial statements. We elected to adopt the modified retrospective application method provided by FAS 123(R), and accordingly, financial statement amounts for the periods presented herein reflect results as if the fair value method of expensing had been applied from the original effective date of FAS 123. Such results are consistent with the previously reported pro forma disclosures required under FAS 123.

As part of our adoption of FAS 123(R), we recorded the cumulative share-based compensation expense, net of taxes, for the period 1995 through 2005, resulting in a reduction of our retained earnings of \$67.1 million and our deferred income tax liability of \$19.6 million, with an offsetting increase to additional paid-in capital of \$86.3 million in the accompanying consolidated balance sheet as of December 31, 2005. The \$19.6 million reduction to our deferred income tax liability represents the cumulative expense related to stock options expected to result in a future tax deduction. Additionally, we reclassified \$425 of deferred compensation to additional paid-in capital as of December 31, 2005.

Our accompanying unaudited consolidated statements of income reflect pre-tax share-based compensation expense of \$4.5 million (\$2.9 million after-tax) and \$13.9 million (\$8.9 million after-tax) for the three and nine months ended September 30, 2006 and \$4.9 million (\$3.1 million after-tax) and \$13.4 million (\$8.5 million after-tax) for the three and nine months ended September 24, 2005. Our basic and diluted earnings from continuing operations per share as originally reported for the three months ended September 24, 2005 were reduced by \$.04 and \$.03 as a result of our modified retrospective application of FAS 123(R). Our basic and diluted earnings from continuing operations per share as originally reported for the nine months ended September 24, 2005 were reduced by \$.10 and \$.09 as a result of our modified retrospective application of FAS 123(R).

Our accompanying unaudited consolidated statements of cash flows present our stock-based compensation expense as an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. Additionally, prior to adopting FAS 123(R), benefits associated with tax deductions in excess of recognized compensation expense were presented as part of operating cash flow on our consolidated statements of cash flows. However, FAS 123(R) requires that such excess tax benefits be presented as a cash inflow from financing activities. In the accompanying consolidated statements of cash flows, we presented \$13.2 million and \$7.5 million of such excess tax benefits as a cash inflow from financing activities for the nine months ended September 30, 2006 and September 24, 2005.

Stock-based compensation represents the cost related to stock-based awards granted to employees and non-employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost as compensation expense on a straight-line basis (net of estimated forfeitures) over the requisite service period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our consolidated statements of income.

Stock-based awards are provided to certain employees and non-employee directors under the terms of our 1994 Stock Incentive Plan, as amended, and our 1996 Non-Employee Director Stock Incentive Plan, as amended (the Plans). The Plans are administered by the Compensation Committee of the Board of Directors. Awards under the Plans principally include a combination of at-the-money stock options and restricted stock (including restricted stock units). As of September 30, 2006, there were 20,157,270 shares

**Table of Contents**

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**(in thousands, except share and per share data)**  
**(unaudited)**

**Note 3. Stock-Based Compensation (Continued)**

authorized and 2,460,404 shares available to be granted under the 1994 Stock Incentive Plan and 800,000 shares authorized and 333,694 shares available to be granted under the 1996 Non-Employee Director Plan.

Stock options are awards that allow the recipient to purchase shares of our common stock at a fixed price. Stock options are granted at an exercise price equal to our closing stock price on the date of grant. These awards, which generally vest 25% per year, are fully vested four years from the grant date and have a contractual term of ten years from the grant date. Additionally, recipients may not sell any shares that they acquire through exercising their options until the third anniversary of the date of grant of such options. We estimate the fair value of stock options using the Black-Scholes valuation model.

Grants of restricted stock are common stock awards granted to recipients with specified vesting provisions. We issue restricted stock that vests based on the recipient's continued service over time (four-year cliff vesting) and restricted stock that vests based on our achieving specified performance measurements (three-year cliff vesting).

With respect to time-based restricted stock, we estimate the fair value on the date of grant based on our closing stock price. With respect to performance-based restricted stock, the number of shares that ultimately vest and are received by the recipient depends on our earnings per share performance measured against specified targets over a three-year period. The fair value of performance-based restricted stock is determined on the date of grant, based on our closing stock price, and assumes that performance targets will be achieved. Over the performance period, the number of shares of common stock that will ultimately vest and be issued is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as expense will be based on a comparison of the final performance metrics to the specified targets.

Restricted stock units (RSUs) are unit awards we grant to certain non-U.S. employees that entitle the recipient to shares of common stock upon vesting after four years for time-based awards or three years for performance-based awards. The fair value of RSUs is determined on the date of grant, based on our closing stock price.

We record deferred tax assets for awards that result in deductions on our income tax returns, based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported on our income tax return are recorded in additional paid-in capital (if the tax deduction exceeds the deferred tax asset) or in earnings (if the deferred tax asset exceeds the tax deduction and no additional paid-in capital exists from previous awards).

The majority of stock-based compensation expense for the nine months ended September 30, 2006 and September 24, 2005 was generated through stock options. The weighted-average grant date fair value of stock-based awards granted was \$386 and \$550 during the three months ended September 30, 2006 and September 24, 2005 and \$24.9 million and \$22.2 million for the nine months ended September 30, 2006 and September 24, 2005. For the three and nine months ended September 30, 2006, the fair value of stock-based awards issued was evenly divided between stock options and restricted stock (including RSUs).

Total unrecognized compensation cost related to non-vested awards as of September 30, 2006 was \$44.3 million, which is expected to be recognized over a weighted-average period of approximately 3 years. There were no significant capitalized stock-based compensation costs as of September 30, 2006.

Table of Contents

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(in thousands, except share and per share data)  
(unaudited)

**Note 3. Stock-Based Compensation (Continued)**

The following table summarizes stock option activity under the Plans during the nine months ended September 30, 2006:

	<b>Shares</b>	<b>Weighted Average Exercise Price</b>
Outstanding at beginning of period	8,882,557	\$ 26.37
Granted	834,316	47.34
Exercised	(1,715,801)	19.18
Forfeited	(223,061)	33.32
Outstanding at end of period	7,778,011	30.00
Options exercisable at end of period	5,329,527	25.23

The shares under option at September 30, 2006, were in the following exercise price ranges:

<b>Options Outstanding</b>				
<b>Range of Exercise Prices</b>	<b>Number</b>	<b>Weighted Average Remaining Contractual Life</b>	<b>Weighted Average Exercise Price</b>	<b>Aggregate Intrinsic Value</b>
	<b>Outstanding</b>	<b>in Years</b>	<b>Price</b>	<b>Value</b>
\$ 5.91 to \$ 9.87	354,217	2.6	\$ 6.89	\$ 15,320,941
10.75 to 15.03	554,340	3.3	13.24	20,456,932
16.10 to 24.13	2,219,959	5.0	19.67	67,636,812
24.41 to 51.10	4,649,495	8.1	38.70	53,198,096
	7,778,011	6.6	30.00	\$ 156,612,781

<b>Options Exercisable</b>				
<b>Range of Exercise Prices</b>	<b>Number</b>	<b>Weighted Average Remaining Contractual Life</b>	<b>Weighted Average Exercise Price</b>	<b>Aggregate Intrinsic Value</b>
	<b>Exercisable</b>	<b>in Years</b>	<b>Price</b>	<b>Value</b>
\$ 5.91 to \$ 9.87	354,217	2.6	\$ 6.89	\$ 15,320,941
10.75 to 15.03	554,340	3.3	13.24	20,456,932
16.10 to 24.13	2,219,959	5.0	19.67	67,636,812
24.41 to 51.10	2,201,011	7.8	36.80	29,354,464

5,329,527

5.8

25.23

\$ 132,769,149

**Table of Contents**

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**(in thousands, except share and per share data)**  
**(unaudited)**

**Note 3. Stock-Based Compensation (Continued)**

The following weighted-average assumptions were used in determining the fair values of stock options using the Black-Scholes valuation model:

	<b>2006</b>	<b>2005</b>
Expected dividend yield	0%	0%
Expected stock price volatility	25%	30%
Risk-free interest rate	4.8%	4.0%
Expected life of options (years)	5	5

We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on our stock, historical volatility of our stock, and other factors. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant in conjunction with considering the expected life of options. The expected life of options is based on historical data on option exercises and represents the approximate period of time that granted options are expected to be outstanding. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by recipients of stock options, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by us.

The total intrinsic value of stock options exercised was \$12.0 million and \$9.4 million for the three months ended September 30, 2006 and September 24, 2005 and \$48.6 million and \$32.7 million for the nine months ended September 30, 2006 and September 24, 2005. The total cash received as a result of stock option exercises for the nine months ended September 30, 2006 and September 24, 2005 was approximately \$32.9 million and \$25.3 million. In connection with these exercises, the tax benefits that we realized for the nine months ended September 30, 2006 and September 24, 2005 were \$17.7 million and \$12.1 million. We settle employee stock option exercises with newly issued common shares.

Table of Contents

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
(in thousands, except share and per share data)  
(unaudited)

**Note 3. Stock-Based Compensation (Continued)**

The total intrinsic value of restricted stock (including RSUs) that vested was \$38 and \$33 during the three months ended September 30, 2006 and September 24, 2005 and \$110 and \$91 during the nine months ended September 30, 2006 and September 24, 2005. The following table summarizes the status of our non-vested restricted shares for the nine months ended September 30, 2006:

	<b>Time-Based Restricted Stock</b>	
	<b>Shares</b>	<b>Weighted Average Grant Date Fair Value</b>
Outstanding at beginning of period	17,478	\$ 424,766
Granted	102,848	4,868,102
Vested	(2,317)	(72,842)
Forfeited	(3,367)	(159,293)
Outstanding at end of period	114,642	\$ 5,060,733

	<b>Performance-Based Restricted Stock</b>	
	<b>Shares</b>	<b>Weighted Average Grant Date Fair Value</b>
Outstanding at beginning of period		
Granted	149,843	\$ 7,091,633
Vested		
Forfeited	(3,367)	(159,293)
Outstanding at end of period	146,476	\$ 6,932,340

**Note 4. Business Acquisitions, Divestiture and Other Transactions***Acquisitions*

On March 31, 2006, we completed the acquisition of NLS Animal Health ( NLS ), a privately held, full-service animal health distribution business with annual revenues of approximately \$110.0 million. We recorded \$53.2 million of goodwill related to this acquisition through a preliminary purchase price allocation.

On June 30, 2006, we acquired certain assets and assumed certain liabilities of a privately held full-service distributor of dental merchandise and equipment. During the third quarter of 2006, we acquired a privately held full-line distributor serving the dental lab community nationwide and a privately held provider of medical supplies and pharmaceutical products including generic drugs, branded drugs and vaccines to small medical practices nationwide. This group of acquisitions (the Darby Group ) has combined annual revenues of approximately \$219.0 million. We recorded \$9.4 million of goodwill related to our acquisition of the Darby Group through a preliminary purchase price allocation.

**Table of Contents**

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**(in thousands, except share and per share data)**  
**(unaudited)**

**Note 4. Business Acquisitions, Divestiture and Other Transactions (Continued)**

In addition to our acquisitions of NLS and the Darby Group, we completed other acquisitions during the nine months ended September 30, 2006. The operating results of our acquisitions were reflected in our financial statements from their respective acquisition dates. Such acquisitions were immaterial to our financial statements individually and in the aggregate.

*Divestiture*

On April 1, 2006, we sold substantially all of the assets of our Hospital Supply Business, previously reported as part of our healthcare distribution reportable segment. The sale price was \$36.5 million, which was received during the second quarter of 2006. As a result of this sale, included in the operating results from discontinued operations for the three months ended April 1, 2006 is a \$32.3 million (\$19.4 million after-tax) loss on the sale, including \$3.5 million (\$2.1 million after-tax) of transitional service obligations and selling costs.

Net sales generated by our Hospital Supply Business were \$37.9 million for the three months ended April 1, 2006 and \$37.3 million and \$112.9 million for the three and nine months ended September 24, 2005. We have classified the operating results of the Hospital Supply Business as a discontinued operation in the accompanying consolidated statements of income for all periods presented. The carrying amounts of the major classes of the Hospital Supply Business assets held-for-sale as of December 31, 2005 included accounts receivable, net of reserves, of approximately \$43.9 million and inventories, net of reserves, of approximately \$16.2 million.

As part of the sale agreement, we are obligated to make payments to the buyer, up to a maximum of \$13.0 million, contingent upon the buyer's collection of specified accounts receivable within one year and the maintenance of a specified level of aggregate sales of the Hospital Supply Business during the two-year post-closing period. Any future payments made in connection with these contingencies will be presented as part of our results from discontinued operations.

*Loan and Investment Agreement*

On July 18, 2006, we loaned D4D Technologies, LLC ( "D4D" ) \$7.6 million and agreed to loan an additional \$5.7 million contingent upon the achievement of specified D4D operational milestones. If such operational milestones are achieved, the additional \$5.7 million loan is expected to be made in the latter part of 2006. The loans will be repayable in July 2013.

We also agreed to make two equity investments in D4D totaling \$27.7 million contingent upon the achievement of specified D4D operational milestones. If such operational milestones are achieved, we expect to make these investments in 2007. We have the option to fund a portion of our second equity investment in D4D by utilizing the loan amounts due to us from D4D. We expect to account for such investments under the equity method prospectively from the date of our first equity investment.

Table of Contents

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**(in thousands, except share and per share data)**  
**(unaudited)**

**Note 5. Earnings Per Share**

Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable upon vesting of restricted stock and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect.

For the three and nine months ended September 30, 2006, diluted earnings per share includes the effect of common shares issuable upon conversion of our convertible debt. During the period, the debt was convertible at a premium as a result of the conditions of the debt, therefore the amount in excess of the principal is presumed to be settled in common shares and is reflected in our calculation of diluted earnings per share.

A reconciliation of shares used in calculating earnings per basic and diluted share follows:

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30, 2006</b>	<b>September 24, 2005</b>	<b>September 30, 2006</b>	<b>September 24, 2005</b>
Basic	88,290,865	87,232,101	87,820,407	86,974,961
Effect of assumed exercise of stock options	1,452,965	1,403,408	1,437,371	1,447,942
Effect of assumed vesting of restricted stock	852		198,288	
Effect of assumed conversion of convertible debt	270,437		98,350	
Diluted	90,015,119	88,635,509	89,554,416	88,422,903

Weighted-average options to purchase 2,388 shares of common stock at exercise prices ranging from \$50.15 to \$51.10 per share and 29,879 shares of common stock at exercise prices ranging from \$42.36 to \$43.19 per share, that were outstanding during the three months ended September 30, 2006 and September 24, 2005, were excluded from the computation of diluted earnings per share. Weighted-average options to purchase 640,546 shares of common stock at exercise prices ranging from \$47.31 to \$51.10 per share and 89,228 shares of common stock at exercise prices ranging from \$39.43 to \$43.19 per share, that were outstanding during the nine months ended September 30, 2006 and September 24, 2005, were excluded from the computation of diluted earnings per share. In each of these periods, such options' exercise prices exceeded the average market price of our common stock, thereby causing the effect of such options to be anti-dilutive.

**Note 6. Comprehensive Income**

Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income, as these amounts are recorded directly as adjustments to stockholders' equity. Our comprehensive income primarily includes net income, foreign currency translation adjustments and unrealized gains and losses on hedging activities. Comprehensive income totaled \$35.7 million and \$120.9 million for the three and nine months ended September 30, 2006, and \$26.9 million and \$71.1 million for the three and nine months ended September 24, 2005.

**Table of Contents**

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**(in thousands, except share and per share data)**  
**(unaudited)**

**Note 6. Comprehensive Income (Continued)**

During the three months ended September 30, 2006, we implemented a change in our method of assessing the amount of effectiveness on all newly transacted net investment hedges to be based on changes in spot exchange rates. Previously, we assessed the amount of effectiveness using a method based on changes in forward exchange rates. This change in method essentially converts certain U.S. LIBOR based borrowings to Euro LIBOR based borrowings allowing us to better align our interest costs and the currency-denomination of funding the business with the geography of our business interests.

With regard to all net investment hedging arrangements which existed at the time of this change, we stopped applying hedge accounting prospectively from the date of change. As a result, during the three months ended September 30, 2006, we recognized a non-recurring pre-tax gain of approximately \$2.0 million, representing the foreign exchange component of our mark-to-market adjustment for the period from the date of change through September 30, 2006.

Additionally, as a result of this change, during the three months ended September 30, 2006, we recognized a reduction in interest expense of approximately \$1.4 million representing the interest rate component of our mark-to-market adjustment. Given current market conditions, we expect further reductions of interest expense into the foreseeable future.

**Note 7. Supplemental Cash Flow Information**

Cash paid for interest and income taxes was:

	<b>Nine Months Ended</b>	
	<b>September 30, 2006</b>	<b>September 24, 2005</b>
Interest	\$26,528	\$ 19,361
Income taxes	54,083	37,948

During the nine months ended September 24, 2005, we had a \$13.8 million non-cash net unrealized gain related to hedging activities reflected in accumulated other comprehensive income on our balance sheet. Additionally, in connection with our acquisition of Austrodent, during the nine months ended September 24, 2005, we reclassified approximately \$12.3 million from other current assets to the respective assets and liabilities acquired.

We have presented the balance of our variable-rate demand notes as part of available-for-sale securities in our consolidated balance sheet. For comparative purposes, we have reclassified approximately \$44.0 million from cash and cash equivalents to available-for-sale securities in our consolidated balance sheet as of December 31, 2005. Additionally, we have adjusted our consolidated statement of cash flows for the nine months ended September 24, 2005 to reflect this reclassification and to reflect the effects of purchasing such available-for-sale securities as a component of net cash used in investing activities.

**Table of Contents**

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Cautionary Note Regarding Forward-Looking Statements**

In accordance with the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors which, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements, or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as may, could, expect, intend, believe, plan, estimate, project, anticipate or other comparable terms.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: competitive factors; changes in the healthcare industry; changes in government regulations that affect us; financial risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service trouble with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; financial risks associated with acquisitions; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

**Executive-Level Overview**

We believe we are the largest distributor of healthcare products and services primarily to office-based healthcare practitioners in the combined North American and European markets. We serve more than 500,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. We believe that we have a strong brand identity due to our 74 years of experience distributing healthcare products.

We are headquartered in Melville, New York, employ more than 11,000 people and have operations in the United States, Canada, the United Kingdom, the Netherlands, Belgium, Germany, France, Austria, Portugal, Spain, the Czech Republic, Luxembourg, Italy, Ireland, Switzerland, Israel, Australia and New Zealand. We also have an affiliate in Iceland.

We have established strategically located distribution centers to enable us to better serve our customers and increase our operating efficiency. This infrastructure, together with broad product and

## **Table of Contents**

service offerings at competitive prices, and a strong commitment to customer service, enables us to be a single source of supply for our customers' needs. Our infrastructure also allows us to provide convenient ordering and rapid, accurate and complete order fulfillment.

We conduct our business through two reportable segments: healthcare distribution and technology. These segments offer different products and services to the same customer base. The healthcare distribution reportable segment aggregates our dental, medical (including animal health) and international operating segments. Products distributed include consumable products, small equipment, laboratory products, large equipment, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Our dental group serves office-based dental practitioners, schools and other institutions in the combined United States and Canadian dental market. Our medical group serves office-based medical practitioners, surgical centers, other alternate-care settings, animal health clinics and other institutions throughout the United States. Our international group serves 17 countries outside of North America and is what we believe to be a leading European healthcare supplier serving office-based practitioners.

Our technology group provides software, technology and other value-added services to healthcare practitioners, primarily in the United States and Canada. Our value-added practice solutions include practice-management software systems for dental and medical practitioners and animal health clinics. Our technology group offerings also include financial services and continuing education services for practitioners.

### *Industry Overview*

In recent years, the healthcare industry has increasingly focused on cost containment. This trend has benefited distributors capable of providing a broad array of products and services at low prices. It also has accelerated the growth of HMOs, group practices, other managed care accounts and collective buying groups, which, in addition to their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing specialized management information support. We believe that the trend towards cost containment has the potential to favorably affect demand for technology solutions, including software, which can enhance the efficiency and facilitation of practice management.

Our operating results in recent years have been significantly affected by strategies and transactions that we undertook to expand our business, domestically and internationally, in part to address significant changes in the healthcare industry, including consolidation of healthcare distribution companies, potential healthcare reform, trends toward managed care, cuts in Medicare and collective purchasing arrangements.

### *Industry Consolidation*

The healthcare products distribution industry, as it relates to office-based healthcare practitioners, is highly fragmented and diverse. This industry, which encompasses the dental, medical and animal health markets, was estimated to produce revenues of approximately \$21.0 billion in 2005 in the combined North American and European markets. The industry ranges from sole practitioners working out of relatively small offices to group practices or service organizations ranging in size from a few practitioners to a large number of practitioners who have combined or otherwise associated their practices.

Due in part to the inability of office-based healthcare practitioners to store and manage large quantities of supplies in their offices, the distribution of healthcare supplies and small equipment to office-based healthcare practitioners has been characterized by frequent, small-quantity orders, and a need for rapid, reliable and substantially complete order fulfillment. The purchasing decisions within an office-based healthcare practice are typically made by the practitioner or an administrative assistant, and supplies and small equipment are generally purchased from more than one distributor, with one generally serving as the primary supplier.

**Table of Contents**

We believe that consolidation within the industry will continue to result in a number of distributors, particularly those with limited financial and marketing resources, seeking to combine with larger companies that can provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire companies that can enhance their current product and service offerings or provide opportunities to serve a broader customer base.

Our trend with regard to acquisitions has been to expand our role as a provider of products and services to the healthcare industry. This trend has resulted in expansion into service areas that complement our existing operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired businesses.

As industry consolidation continues, we believe that we are positioned to capitalize on this trend, as we believe we have the ability to support increased sales through our existing infrastructure. In the U.S. dental market, we estimate that there are currently more than 300 smaller distributors holding over 35% of the market. In the U.S. medical market, we estimate that more than 500 smaller distributors hold over 50% of the market, and in the European dental market, we estimate that more than 200 smaller distributors hold over 80% of the market.

As the healthcare industry continues to change, we continually evaluate possible candidates for merger or acquisition and intend to continue to seek opportunities to expand our role as a provider of products and services to the healthcare industry. There can be no assurance that we will be able to successfully pursue any such opportunity or consummate any such transaction, if pursued. If additional transactions are entered into or consummated, we would incur additional merger and acquisition-related costs, and there can be no assurance that the integration efforts associated with any such transaction would be successful.

*Aging Population and Other Market Influences*

The healthcare products distribution industry continues to experience growth due to the aging population, increased healthcare awareness, the proliferation of medical technology and testing, new pharmacology treatments and expanded third-party insurance coverage. In addition, the physician market continues to benefit from the shift of procedures and diagnostic testing from hospitals to alternate-care sites, particularly physicians' offices. As the cosmetic surgery and elective procedure markets continue to grow, physicians are increasingly performing more of these procedures in their offices. The elder-care market continues to benefit from the increasing growth rate of the population of elderly Americans.

The January 2000 U.S. Bureau of the Census estimated that the elderly population in the United States will more than double by the year 2040. In 2000, four million Americans were aged 85 or older, the segment of the population most in need of long-term care and elder-care services. By the year 2040, that number is projected to more than triple to more than 14 million. The population aged 65 to 84 years is projected to more than double in the same time period.

As a result of these market dynamics, the annual expenditures for healthcare services continue to increase in the United States. The Centers for Medicare and Medicaid Services (CMS) published National Health Care Expenditures Projections: 2005–2015 indicating that total national healthcare spending reached \$1.9 trillion in 2004, or 16.0% of the nation's gross domestic product, the benchmark measure for annual production of goods and services in the United States. Healthcare spending is projected to reach \$4.0 trillion in 2015, an estimated 20.0% of the nation's gross domestic product.

**Table of Contents****Results of Operations**

The following table summarizes the significant components of our operating results from continuing operations and cash flows for the three and nine months ended September 30, 2006 and September 24, 2005 (in thousands):

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30, 2006</b>	<b>September 24, 2005 (1)</b>	<b>September 30, 2006</b>	<b>September 24, 2005 (1)</b>
<b>Operating Results:</b>				
Net sales	\$ 1,272,020	\$ 1,125,363	\$ 3,654,161	\$ 3,292,788
Cost of sales	911,014	808,632	2,596,093	2,353,327
Gross profit	361,006	316,731	1,058,068	939,461
Operating expenses:				
Selling, general and administrative	298,331	258,352	857,727	760,762
Operating income	\$ 62,675	\$ 58,379	\$ 200,341	\$ 178,699
Other expense, net	\$ (740)	\$ (4,006)	\$ (7,029)	\$ (12,902)
Income from continuing operations	39,285	33,304	120,130	101,577
<b>Cash Flows:</b>				
Net cash provided by operating activities			\$ 64,626	\$ 106,048
Net cash used in investing activities (2)			99,021	83,515
Net cash used in financing activities			8,365	6,935

(1) Adjusted to reflect the effect of our adoption of FAS 123(R) using the modified retrospective application.

(2) Adjusted to reflect the reclassification of variable rate demand notes from cash and cash equivalents to available-for-sale securities at September 24, 2005.

**Three Months Ended September 30, 2006 Compared to Three Months Ended September 24, 2005*****Net Sales***

# Edgar Filing: HENRY SCHEIN INC - Form 10-Q

Net sales from continuing operations for the three months ended September 30, 2006 and September 24, 2005 were as follows (in thousands):

	<b>September 30, 2006</b>	<b>% of Total</b>	<b>September 24, 2005</b>	<b>% of Total</b>
Healthcare distribution (1):				
Dental (2)	\$ 538,493	42.3%	\$ 462,514	41.1%
Medical (3)	381,435	30.0	350,185	31.1
International (4)	327,499	25.8	291,701	25.9
Total healthcare distribution	1,247,427	98.1	1,104,400	98.1
Technology (5)	24,593	1.9	20,963	1.9
Total	\$ 1,272,020	100.0%	\$ 1,125,363	100.0%

(1) Consists of consumable products, small equipment, laboratory products, large equipment, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2) Consists of products sold in the United States and Canada.

(3) Consists of products sold in the United States medical and animal health markets.

(4) Consists of products sold in the dental, medical and animal health markets, primarily in Europe.

(5) Consists of practice-management software and other value-added products

and services, which  
are distributed  
primarily to  
healthcare providers  
in the United States  
and Canada.

**Table of Contents**

The \$146.7 million, or 13.0%, increase in net sales for the three months ended September 30, 2006, includes increases of 11.6% local currency growth (5.0% internally generated primarily due to volume growth and 6.6% from acquisitions, net of divestiture) and 1.4% related to foreign currency exchange.

The \$76.0 million, or 16.4%, increase in dental net sales for the three months ended September 30, 2006, includes increases of 15.6% local currency growth (9.8% internally generated primarily due to volume growth and 5.8% from acquisitions) and 0.8% related to foreign currency exchange. The 15.6% local currency growth was due to dental consumable merchandise sales growth of 14.2% (8.1% internal growth and 6.1% acquisition growth) and dental equipment sales and service growth of 20.1% (15.4% internal growth, primarily due to sales of high-tech equipment, and 4.7% acquisition growth).

The \$31.3 million, or 8.9%, increase in medical net sales for the three months ended September 30, 2006, includes acquisition growth, net of divestiture, of 9.5%, offset by a decline in net sales of 0.6% primarily due to timing differences in our receipt and sale of influenza and tetanus-diphtheria vaccines.

The \$35.8 million, or 12.3%, increase in international net sales for the three months ended September 30, 2006, includes increases of 8.2% in local currencies (3.4% internally generated primarily due to volume growth and 4.8% from acquisitions), and 4.1% related to foreign currency exchange.

The \$3.6 million, or 17.3%, increase in technology net sales for the three months ended September 30, 2006, includes increases of 16.9% in local currency growth (14.7% internally generated primarily due to volume growth and 2.2% from acquisitions) and 0.4% related to foreign currency exchange. The increase was primarily due to increased electronic, software and financial services sales.

**Gross Profit**

Gross profit and gross margin percentages from continuing operations by segment and in total for the three months ended September 30, 2006 and September 24, 2005 were as follows (in thousands):

	September 30, 2006	Gross Margin %	September 24, 2005	Gross Margin %
Healthcare distribution	\$ 342,197	27.4%	\$ 300,787	27.2%
Technology	18,809	76.5	15,944	76.1
Total	\$ 361,006	28.4	\$ 316,731	28.1

For the three months ended September 30, 2006, gross profit increased \$44.3 million, or 14.0%, from the comparable prior year period. As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we realize substantially higher gross margin percentages in our technology segment than in our healthcare distribution segment. These higher gross margins result from being both the developer and seller of software products combined with the nature of the software industry, in which developers typically realize higher gross margins to recover investments in research and development.

Healthcare distribution gross profit increased \$41.4 million, or 13.8%, for the three months ended September 30, 2006 from the comparable prior year period. Healthcare distribution gross profit margin increased to 27.4% for the three months ended September 30, 2006 from 27.2% for the comparable prior year period, which reflects favorable sales mix and improved margin management.

**Table of Contents**

Technology gross profit increased \$2.9 million, or 18.0%, for the three months ended September 30, 2006 from the comparable prior year period. Technology gross profit margin increased to 76.5% for the three months ended September 30, 2006 from 76.1% for the comparable prior year period primarily due to a favorable sales mix of higher margin product sales.

***Selling, General and Administrative***

Selling, general and administrative expenses from continuing operations by segment and in total for the three months ended September 30, 2006 and September 24, 2005 were as follows (in thousands):

	September 30, 2006	% of Respective Net Sales	September 24, 2005 (1)	% of Respective Net Sales
Healthcare distribution	\$ 287,952	23.1%	\$ 250,183	22.7%
Technology	10,379	42.2	8,169	39.0
Total	\$ 298,331	23.5	\$ 258,352	23.0

(1) Adjusted to reflect the effect of our adoption of FAS 123(R) using the modified retrospective application.

Selling, general and administrative expenses increased \$40.0 million, or 15.5%, to \$298.3 million for the three months ended September 30, 2006 from the comparable prior year period. As a percentage of net sales, selling, general and administrative expenses increased to 23.5% from 23.0% for the comparable prior year period. The increase was primarily due to payroll and expenses related to recent acquisitions as well as certain non-recurring charges.

As a component of selling, general and administrative expenses, selling expenses increased \$27.0 million, or 14.9%, to \$207.7 million for the three months ended September 30, 2006 from the comparable prior year period. As a percentage of net sales, selling expenses increased to 16.3% from 16.1% for the comparable prior year period.

As a component of selling, general and administrative expenses, general and administrative expenses increased \$13.0 million, or 16.8%, to \$90.6 million for the three months ended September 30, 2006 from the comparable prior year period. As a percentage of net sales, general and administrative expenses increased to 7.1% from 6.9% for the comparable prior year period.

***Other Expense, Net***

Other expense, net from continuing operations for the three months ended September 30, 2006 and September 24, 2005 were as follows (in thousands):

	September 30, 2006	September 24, 2005
Interest income	\$ 3,503	\$ 1,942
Interest expense	(6,541)	(6,976)
Other, net	2,298	1,028

Other expense, net	\$	(740)	\$	(4,006)
--------------------	----	-------	----	---------

Other expense, net decreased \$3.3 million for the three months ended September 30, 2006 from the comparable prior year period. This change was primarily due to a \$1.6 million increase in interest income resulting from higher interest rates and a \$1.3 million increase in other income, net resulting from a \$2.0 million non-recurring foreign exchange gain (discussed in Note 6 to our consolidated financial statements)

**Table of Contents**

contained herein) partially offset by other fluctuations in foreign exchange. Further contributing to the change was a \$435 decrease in interest expense which was primarily due to a \$1.4 million decrease in interest expense related to implementing a change in our method of assessing hedge effectiveness (discussed in Note 6 to our consolidated financial statements contained herein) partially offset by higher interest rates.

***Income Taxes***

For the three months ended September 30, 2006, our effective tax rate from continuing operations decreased to 35.1% from 36.6% for the comparable prior year period. The difference between our effective tax rates and the federal statutory tax rates for both periods related primarily to foreign and state income taxes.

**Nine Months Ended September 30, 2006 Compared to Nine Months Ended September 24, 2005*****Net Sales***

Net sales from continuing operations for the nine months ended September 30, 2006 and September 24, 2005 were as follows (in thousands):

	<b>September 30, 2006</b>	<b>% of Total</b>	<b>September 24, 2005</b>	<b>% of Total</b>
Healthcare distribution (1):				
Dental (2)	\$ 1,532,399	41.9%	\$ 1,361,183	41.3%
Medical (3)	1,064,669	29.1	968,633	29.4
International (4)	986,338	27.0	898,479	27.3
Total healthcare distribution	3,583,406	98.0	3,228,295	98.0
Technology (5)	70,755	2.0	64,493	2.0
Total	\$ 3,654,161	100.0%	\$ 3,292,788	100.0%

(1) Consists of consumable products, small equipment, laboratory products, large equipment, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2) Consists of products sold in the United States and Canada.

(3) Consists of products sold in the United States medical and animal health

markets.

- (4) Consists of products sold in the dental, medical and animal health markets, primarily in Europe.
- (5) Consists of practice-management software and other value-added products and services, which are distributed primarily to healthcare providers in the United States and Canada.

The \$361.4 million, or 11.0%, increase in net sales for the nine months ended September 30, 2006, includes increases of 11.2% local currency growth (6.3% internally generated primarily due to volume growth and 4.9% from acquisitions, net of divestiture), offset by a 0.2% decline related to foreign currency exchange.

The \$171.2 million, or 12.6%, increase in dental net sales for the nine months ended September 30, 2006, includes increases of 11.6% local currency growth (9.3% internally generated primarily due to volume growth and 2.3% from acquisitions) and 1.0% related to foreign currency exchange. The 11.6% local currency growth was due to dental consumable merchandise sales growth of 10.3% (8.0% internal growth and 2.3% acquisition growth) and dental equipment sales and service growth of 16.0% (13.9% internal growth, primarily due to sales of high-tech equipment, and 2.1% acquisition growth).

The \$96.0 million, or 9.9%, increase in medical net sales for the nine months ended September 30, 2006, includes internal growth of 2.5%, primarily due to volume growth and timing differences in our

**Table of Contents**

receipt and sale of influenza and tetanus-diphtheria vaccines, and acquisition growth, net of divestiture, of 7.4%.

The \$87.9 million, or 9.8%, increase in international net sales for the nine months ended September 30, 2006, includes increases of 11.9% in local currencies (5.8% internally generated primarily due to volume growth and 6.1% from acquisitions), offset by a 2.1% decline related to foreign currency exchange.

The \$6.3 million, or 9.7%, increase in technology net sales for the nine months ended September 30, 2006, includes increases of 9.3% in local currency growth (8.6% internally generated primarily due to volume growth and 0.7% from acquisitions) and 0.4% due to foreign currency exchange. The increase was primarily due to increased electronic, software and financial services sales.

***Gross Profit***

Gross profit and gross margin percentages from continuing operations by segment and in total for the nine months ended September 30, 2006 and September 24, 2005 were as follows (in thousands):

	September 30, 2006	Gross Margin %	September 24, 2005	Gross Margin %
Healthcare distribution	\$ 1,003,772	28.0%	\$ 890,295	27.6%
Technology	54,296	76.7	49,166	76.2
Total	\$ 1,058,068	29.0	\$ 939,461	28.5

For the nine months ended September 30, 2006, gross profit increased \$118.6 million, or 12.6%, from the comparable prior year period.

Healthcare distribution gross profit increased \$113.5 million, or 12.7%, for the nine months ended September 30, 2006 from the comparable prior year period. Healthcare distribution gross profit margin increased to 28.0% for the nine months ended September 30, 2006 from 27.6% for the comparable prior year period, which reflects favorable sales mix and improved margin management.

Technology gross profit increased \$5.1 million, or 10.4%, for the nine months ended September 30, 2006 from the comparable prior year period. Technology gross profit margin increased slightly to 76.7% for the nine months ended September 30, 2006 from 76.2% for the comparable prior year period.

***Selling, General and Administrative***

Selling, general and administrative expenses from continuing operations by segment and in total for the nine months ended September 30, 2006 and September 24, 2005 were as follows (in thousands):

	September 30, 2006	% of Respective Net Sales	September 24, 2005 (1)	% of Respective Net Sales
Healthcare distribution	\$ 829,750	23.2%	\$ 736,146	22.8%
Technology	27,977	39.5	24,616	38.2
Total	\$ 857,727	23.5	\$ 760,762	23.1

(1) Adjusted to reflect the effect of our adoption of FAS 123(R)

using the  
modified  
retrospective  
application.

**Table of Contents**

Selling, general and administrative expenses increased \$97.0 million, or 12.7%, to \$857.7 million for the nine months ended September 30, 2006 from the comparable prior year period. As a percentage of net sales, selling, general and administrative expenses increased to 23.5% from 23.1% for the comparable prior year period. The increase was primarily due to payroll and expenses related to recent acquisitions as well as certain non-recurring charges.

As a component of selling, general and administrative expenses, selling expenses increased \$69.2 million, or 13.7%, to \$576.6 million for the nine months ended September 30, 2006 from the comparable prior year period. As a percentage of net sales, selling expenses increased to 15.8% from 15.4% for the comparable prior year period.

As a component of selling, general and administrative expenses, general and administrative expenses increased \$27.8 million, or 10.9%, to \$281.1 million for the nine months ended September 30, 2006 from the comparable prior year period. As a percentage of net sales, general and administrative expenses were 7.7% for the nine months ended September 30, 2006 and September 24, 2005.

***Other Expense, Net***

Other expense, net from continuing operations for the nine months ended September 30, 2006 and September 24, 2005 were as follows (in thousands):

	<b>September 30, 2006</b>	<b>September 24, 2005</b>
Interest income	\$ 12,028	\$ 4,469
Interest expense	(21,237)	(18,286)
Other, net	2,180	915
Other expense, net	\$ (7,029)	\$ (12,902)

Other expense, net decreased \$5.9 million for the nine months ended September 30, 2006 from the comparable prior year period. This change was primarily due to a \$7.6 million increase in interest income resulting from higher interest rates and a \$1.3 million increase in other income, net resulting from a \$2.0 million non-recurring foreign exchange gain (discussed in Note 6 to our consolidated financial statements contained herein) partially offset by other fluctuations in foreign exchange. Further contributing to the change was a \$3.0 million increase in interest expense which was primarily due to higher interest rates partially offset by \$1.4 million decrease in interest expense related to implementing a change in our method of assessing hedge effectiveness (discussed in Note 6 to our consolidated financial statements contained herein).

***Income Taxes***

For the nine months ended September 30, 2006, our effective tax rate from continuing operations decreased to 35.9% from 36.8% for the comparable prior year period. The difference between our effective tax rates and the federal statutory tax rates for both periods related primarily to foreign and state income taxes.

**Table of Contents****Liquidity and Capital Resources**

Our principal capital requirements include the funding of working capital needs, acquisitions, capital expenditures and repurchases of common stock. Working capital requirements generally result from increased sales, special inventory forward buy-in opportunities, and payment terms for receivables and payables. Since sales tend to be stronger during the third and fourth quarters and special inventory forward buy-in opportunities are most prevalent just before the end of the year, our working capital requirements have generally been higher from the end of the third quarter to the end of the first quarter of the following year.

We finance our business primarily through cash generated from our operations, revolving credit facilities, debt placements and stock issuances. Our ability to generate sufficient cash flows from operations is dependent on the continued demand of our customers for, and supply by our vendors of, our products and services. Given current operating, economic and industry conditions, we believe that demand for our products and services will remain consistent in the foreseeable future. We do not expect the loss of cash flows from discontinued operations to have a material impact on our future liquidity or capital resources.

Net cash flow provided by operating activities was \$64.6 million for the nine months ended September 30, 2006, compared to \$106.0 million for the comparable prior year period. This net change of \$41.4 million was due primarily to timing changes in inventory and other current assets, partially offset by timing changes in accounts receivable, accounts payable and accrued expenses, as well as increased sales volume.

Net cash used in investing activities was \$99.0 million for the nine months ended September 30, 2006, compared to \$83.5 million for the comparable prior year period. The net change of \$15.5 million was primarily due to acquisitions, net settlements of foreign exchange forward contracts and purchases of fixed assets, partially offset by proceeds received from a business divestiture and net proceeds from the sale of security transactions. We expect to invest up to approximately \$20.0 million during the remainder of the fiscal year in capital projects to modernize and expand our facilities and computer systems infrastructure and to integrate subsidiary operations into our core infrastructure.

Net cash used in financing activities was \$8.4 million for the nine months ended September 30, 2006, compared to \$6.9 million used in financing activities for the comparable prior year period. The net change of \$1.5 million was primarily due to increased repayments of long-term debt primarily related to the initial payment on our \$100.0 million senior notes, partially offset by increased proceeds from the exercise of stock options and increased proceeds from the excess tax benefits related to stock-based compensation.

The following table summarizes selected measures of liquidity and capital resources (in thousands):

	<b>September 30, 2006</b>	<b>December 31, 2005 (1)</b>
Cash and cash equivalents	\$ 176,070	\$ 210,683
Available-for-sale securities		124,010
Working capital	792,404	860,295
Debt:		
Bank credit lines	\$ 2,550	\$ 2,093
Current maturities of long-term debt	40,617	33,013
Long-term debt	456,487	489,520
Total debt	\$ 499,654	\$ 524,626

(1) Adjusted to  
reflect our  
reclassification of  
variable-rate

demand notes  
from cash and  
cash equivalents  
to  
available-for-sale  
securities within  
our consolidated  
balance sheet.

25

---

## **Table of Contents**

Our cash and cash equivalents consist of bank balances and investments in money market funds representing overnight investments with a high degree of liquidity. At December 31, 2005, our available-for-sale securities consisted of highly liquid tax-efficient securities, including primarily auction-rate securities and variable-rate demand notes.

Our business requires a substantial investment in working capital, which is susceptible to large variations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity, special inventory forward buy-in opportunities and our desired level of inventory.

Our accounts receivable days sales outstanding from continuing operations improved to 42.5 days for the nine months ended September 30, 2006 from 43.9 days for the comparable prior year period. During the three months ended September 30, 2006, we wrote-off approximately \$3.7 million of fully reserved accounts receivable against our trade receivable reserve, which had no effect on our earnings. Our inventory turnover from continuing operations for the nine months ended September 30, 2006 was 6.5 turns compared to 6.6 turns for the nine months ended September 24, 2005. We anticipate future increases in the value of our working capital as a result of continued sales growth.

In 2004, we completed an issuance of \$240.0 million of convertible debt. These notes are senior unsecured obligations bearing a fixed annual interest rate of 3.0% and are due to mature on August 15, 2034. Interest on the notes is payable on February 15 and August 15 of each year, and commenced on February 15, 2005. The notes are convertible into our common stock at a conversion ratio of 21.58 shares per one thousand dollars of principal amount of notes, which is the equivalent conversion price of \$46.34 per share, under the following circumstances:

if the last price of our common stock is above 130% of the conversion price measured over a specified number of trading days;

during the five business-day period following any 10 consecutive trading-day period in which the average of the trading prices for the notes for that 10 trading-day period was less than 98% of the average conversion value for the notes during that period;

if the notes have been called for redemption; or

upon the occurrence of a fundamental change or specified corporate transactions, as defined in the note agreement.

Upon conversion, we are required to satisfy our conversion obligation with respect to the principal amount of the notes to be converted, in cash, with any remaining amount to be satisfied in shares of our common stock. We currently have sufficient availability of funds through our \$300.0 million revolving credit facility (discussed below) along with cash on hand to fully satisfy the cash portion of our conversion obligation. We also will pay contingent interest during any six-month interest period beginning August 20, 2010, if the average trading price of the notes is above specified levels. We may redeem some or all of the notes on or after August 20, 2010. The note holders may require us to purchase all or a portion of the notes on August 15, 2010, 2014, 2019, 2024 and 2029 or, subject to specified exceptions, upon a change of control event.

Our \$130.0 million senior notes are due on June 30, 2009 and bear interest at a fixed rate of 6.94% per annum. On September 25, 2006, we made our first annual principal payment of \$20.0 million on our \$100.0 million senior notes which bear interest at a fixed rate of 6.66% per annum. Interest on both notes is payable semi-annually.

## **Table of Contents**

In 2003, we entered into agreements relating to our \$230.0 million senior notes to exchange their fixed interest rates for variable interest rates. For the nine months ended September 30, 2006, the weighted-average variable interest rate was 7.96%. This weighted-average variable interest rate is comprised of LIBOR plus a spread and resets on the interest due dates for such senior notes.

On May 24, 2005, we entered into a \$300.0 million revolving credit facility with a \$100.0 million expansion feature. This facility, which expires in May 2010, replaced our previous revolving credit facility of \$200.0 million, which was scheduled to expire in May 2006. As of September 30, 2006, there were \$8.2 million of letters of credit provided to third parties and no borrowings outstanding under this revolving credit facility.

On June 21, 2004, we announced that our Board of Directors had authorized a common stock repurchase program. This program previously allowed us to repurchase up to \$100.0 million in shares of our common stock, which represented approximately 3.5% of the shares outstanding on the announcement date. On October 31, 2005, our Board of Directors authorized an additional \$100.0 million of shares of our common stock to be repurchased under this program. As of September 30, 2006, we had repurchased \$114.2 million or 3,078,005 shares under this initiative, with \$85.8 million remaining for future common stock share repurchases.

Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at a price that approximates fair value pursuant to a formula price as defined in the agreements. Additionally, some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain profitability targets are met. We accrue liabilities that may arise from these transactions when we believe that the outcome of the contingency is determinable beyond a reasonable doubt.

We finance our business to provide adequate funding for at least 12 months. Funding requirements are based on forecasted profitability and working capital needs, which, on occasion, may change. Consequently, we may change our funding structure to reflect any new requirements.

We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets, and our available funds under existing credit facilities provide us with sufficient liquidity to meet our currently foreseeable short-term and long-term capital needs.

### **E-Commerce**

Traditional healthcare supply and distribution relationships are being challenged by electronic online commerce solutions. Our distribution business is characterized by rapid technological developments and intense competition. The advancement of online commerce will require us to cost-effectively adapt to changing technologies, to enhance existing services and to develop and introduce a variety of new services to address the changing demands of consumers and our customers on a timely basis, particularly in response to competitive offerings.

Through our proprietary, technologically-based suite of products, we offer customers a variety of competitive alternatives. We believe that our tradition of reliable service, our name recognition and large customer base built on solid customer relationships position us well to participate in this growing aspect of the distribution business. We continue to explore ways and means to improve and expand our Internet presence and capabilities.

**Table of Contents**

**Critical Accounting Policies and Estimates**

There have been no material changes in our critical accounting policies and estimates from those disclosed in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2005, except as discussed in Note 6 to our consolidated financial statements contained herein.

**Recently Issued Accounting Standards**

In July 2006, the Financial Accounting Standards Board ( FASB ) issued FAS Interpretation No. 48, Accounting for Uncertainty in Income Taxes an interpretation of FAS No. 109 ( FIN 48 ). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with FAS No. 109, Accounting for Income Taxes. FIN 48 prescribes a recognition threshold and measurement attribute for a tax position taken or expected to be taken in a tax return. FIN 48 also provides guidance on future changes, classification, interest and penalties, accounting in interim periods, disclosures and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006. We are currently evaluating the impact of FIN 48 on our consolidated financial statements.

In September 2006, the FASB issued FAS No. 157, Fair Value Measurements. FAS 157 establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. FAS 157 applies under other previously issued accounting pronouncements that require or permit fair value measurements but does not require any new fair value measurements. FAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. We are currently evaluating the impact of FAS 157 on our consolidated financial statements.

In September 2006, the Securities and Exchange Commission ( SEC ) issued Staff Accounting Bulletin ( SAB ) No. 108, Quantifying Financial Statement Misstatements. The SEC staff is aware of diversity in practice regarding the process of quantifying financial statement misstatements. The SEC has voiced concerns over registrants exclusive reliance on either a balance sheet or income statement approach in assessing the materiality of financial statement misstatements. SAB 108 states that registrants should use both a balance sheet approach and income statement approach when quantifying and evaluating the materiality of a misstatement. The SAB also provides guidance on correcting errors under the dual approach, as well as transition guidance for correcting previously immaterial errors that are now considered material based on the approach in the SAB. We are in compliance with SAB 108.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

There have been no material changes in our exposure to market risk from that disclosed in Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2005.

**Table of Contents**

**ITEM 4. CONTROLS AND PROCEDURES**

*Evaluation of Disclosure Controls and Procedures*

Under the supervision and with the participation of management, including our principal executive officer and principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this quarterly report as such term is defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act). Based on this evaluation, our management, including our principal executive officer and principal financial officer, concluded that our disclosure controls and procedures were effective as of September 30, 2006 to ensure that all material information required to be disclosed by us in reports that we file or submit under the Exchange Act is accumulated and communicated to them as appropriate to allow timely decisions regarding required disclosure and that all such information is recorded, processed, summarized and reported as specified in the SEC's rules and forms.

*Changes in Internal Control Over Financial Reporting*

There have been no individual changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2006 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. However, there have been a number of initiatives which have carried over from prior quarters, or commenced this quarter, relating to acquisition integrations and system implementations, that when considered in the aggregate, currently represent a material change in our internal control over financial reporting.

Acquisitions, including NLS Animal Health and Provet, with approximate aggregate annual revenues of \$189.0 million, each utilizing separate information and financial accounting systems, have been included in our consolidated financial statements. In addition, acquisitions occurring during the quarter including the Darby Group, with approximate aggregate annual revenues of \$221.0 million have been integrated into our existing enterprise resource planning (ERP) system in the United States and are covered by our existing system of internal control over financial reporting. Finally, there have been ongoing implementations of new ERP systems by existing business units with approximate aggregate annual revenues of \$312.0 million.

All acquisitions, acquisition integrations and new system implementations involve necessary and appropriate change-management controls that are considered in our annual assessment of the design and operating effectiveness of our internal control over financial reporting. We expect our assessment of these changes in internal control to be completed in 2006.

*Limitations of the Effectiveness of Internal Control*

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the internal control system are met. Because of the inherent limitations of any internal control system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

**Table of Contents**

**PART II. OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

Our business involves a risk of product liability claims and other claims in the ordinary course of business. Additionally, from time to time we are named as a defendant in cases as a result of our distribution of pharmaceutical and other healthcare products. As a business practice, we generally obtain product indemnification from our suppliers.

We have various insurance policies, including product liability insurance, covering risks in amounts that we consider adequate. In many cases in which we have been sued in connection with products manufactured by others, the manufacturer provides us with indemnification. There can be no assurance that the insurance coverage we maintain is sufficient or will be available in adequate amounts or at a reasonable cost, or that indemnification agreements will provide us with adequate protection. In our opinion, all pending matters, including those described below, are covered by insurance or will not otherwise have a material adverse effect on our financial condition or results of operations.

As of September 30, 2006, we had accrued our best estimate of potential losses relating to product liability and other claims that were probable to result in a liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other external factors, including probable recoveries from third parties.

**Product Liability Claims**

As of September 30, 2006, we were a defendant in approximately 49 product liability cases. In many of these cases, the manufacturers have agreed to defend and indemnify us. The manufacturers have withheld defense and indemnification in some of these cases pending product identification. In our opinion, these cases are covered by insurance or will not otherwise have a material adverse effect on our financial condition or results of operations.

**Table of Contents****ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS***Purchases of equity securities by the issuer*

Our current share repurchase program, announced on June 21, 2004, originally allowed us to repurchase up to \$100.0 million in shares of our common stock, which represented approximately 3.5% of the shares outstanding at the commencement of the program. On October 31, 2005, our Board of Directors authorized an additional \$100.0 million of shares of our common stock to be repurchased under this program. As of September 30, 2006, we had repurchased \$114.2 million or 3,078,005 shares under this initiative, with \$85.8 million remaining for future common stock share repurchases.

The following table summarizes repurchases of our common stock under our stock repurchase program during the fiscal quarter ended September 30, 2006:

<b>Fiscal Month</b>	<b>Total Number of Shares Purchased (1)</b>	<b>Average Price Paid per Share</b>	<b>Total Number of Shares Purchased as Part of Our Publicly Announced Program</b>	<b>Maximum Number of Shares that May Yet Be Purchased Under Our Program (2)</b>
07/02/06 through 08/05/06	40,000	\$47.29	40,000	1,813,579
08/06/06 through 09/02/06	7,861	46.96	7,861	1,710,387
09/03/06 through 09/30/06				1,710,728
<b>Total</b>	<b>47,861</b>		<b>47,861</b>	

(1) All repurchases were executed in the open market under our existing publicly announced authorized program.

(2) The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the closing price of our common stock at that time.



**Table of Contents**

**ITEM 6. EXHIBITS**

Exhibits.

31.1 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Henry Schein, Inc.  
(Registrant)

By: /s/ Steven Paladino  
Steven Paladino  
Executive Vice President and  
Chief Financial Officer  
(Authorized Signatory and Principal  
Financial and Accounting Officer)

Dated: November 8, 2006